Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
Fiche publication
Date publication
avril 2018
Journal
American heart journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre, Pr DI MARTINO Vincent, Pr THIEFIN Gérard
Tous les auteurs :
Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E,
Lien Pubmed
Résumé
The objective was to examine the role of a sustained virological response (SVR) on major adverse cardiovascular events (MACEs) in patients with compensated hepatitis C virus (HCV) cirrhosis.
Mots clés
Age Distribution, Aged, Antiviral Agents, therapeutic use, Biopsy, Needle, Cardiovascular Diseases, epidemiology, Cohort Studies, Female, France, Hepatitis C, Chronic, complications, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Liver Cirrhosis, complications, Liver Function Tests, Male, Middle Aged, Predictive Value of Tests, Prevalence, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Severity of Illness Index, Sex Distribution, Survival Rate
Référence
Am. Heart J.. 2018 Apr;198:4-17